TRICARE Prior Authorization Request Form for liraglutide 3 mg injection (**Saxenda**), semaglutide 2.4mg injection (**Wegovy**)

tirzepatide injection (Zepbound)



P377

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) TRICARE pharmacy program (TPHARM). Express Scripts is the TPHARM contractor for DoD.

PLEASE NOTE: For Active Duty Service Members, even if coverage will NOT BE APPROVED per this form, it still must be initially submitted to the TPharm Contractor for review. Subsequent reconsideration is allowed at the appropriate Military Treatment Facility. Providers must continue to follow Military Department-specific policies that set the requirements for participation in weight loss programs for Active-Duty Service Members.

For initial review by the TPharm Contractor;

 The provider may call: 1-866-684-4488 or the completed form may be faxed to: 1-866-684-4477

The patient may attach the completed form
to the prescription and mail it to: Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954
or email the form only to:
TPharmPA@express-scripts.com

Initial therapy approves for 6 months, renewal approves for 12 months. For renewal of therapy an initial Tricare prior authorization approval is required.

iricare	orior authorization approval	is requirea.					
Step	Please complete patient and physician information (please print):						
1	Patient Name: Address: Sponsor ID # Date of Birth:		Physician Name:				
			Address:				
			Phone #:				
			Secure Fax #:				
Step 2	Please complete the clinical assessment:						
	1. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for the requested medication.		☐ Yes	□ No			
			(subject to verification)	Proceed to question 2			
			Proceed to question 15	·			
	2. How old is the patient?		☐ Less than 12 years of age - STOP Coverage not approved				
			☐ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question 3				
			☐ Greater than or equal to 18 years of age - Proceed to question 6				
		Does the patient have BMI GREATER THAN OR EQUAL TO the 95th percentile standardized for age and sex?	☐ Yes	□ No			
			Proceed to question 4	STOP			
	3			Coverage not approved			
	•	Has the patient tried and failed or has a contraindication to Qsymia or one of its individual generic components?	☐ Yes	□ No			
			Proceed to question 5	STOP			
	marriada generio componento:			Coverage not approved			

TRICARE Prior Authorization Request Form for liraglutide 3 mg injection (Saxenda), semaglutide 2.4mg injection (Wegovy) tirzepatide injection (Zepbound)

5.	Please provide the date and duration or contraindication for each medication listed below. Note: The dates and durations of therapy for each medication or contraindication to each medication listed below must be provided or your case could be denied.							
	Qsymia or one of its individual generic components:							
	-	Duration of therapy						
	Proceed to question 9							
6.	Does the patient have BMI GREATER THAN or EQUAL to 30, or a BMI GREATER THAN or EQUAL to 27 for those with risk factors in addition to obesity (diabetes, impaired glucose tolerance, dyslipidemia, hypertension, sleep apnea)?		☐ Yes	□ No				
			Proceed to question 7	STOP				
				Coverage not approved				
7.	Has the patient tried and failed or has a		☐ Yes	□ No				
		on to phentermine, Qsymia or one I generic components, and	Proceed to question 8	STOP				
	Contrave or one of its individual generic components?			Coverage not approved				
8.	Please provide	the date and duration or contraindic	ation for each medication	listed below.				
		s and durations of therapy for each i ust be provided or your case could b		tion to each medication				
Phente		Duration of therapy		lication				
Qsymi	a or one of its inc	dividual generic components - topira	mate and phentermine:					
Date _		Duration of therapy	Contraindication _					
Contra	ve or one of its i	ndividual generic components - bupi	opion and naltrexone:					
Date _		Duration of therapy	Contraindication _					
		D	ation 0					
		Proceed to que						
9.	Does the patier	nt have type 2 diabetes?	☐ Yes	□ No				
			Proceed to question 10	Proceed to question 11				
10. Has the patient tried and failed metformin and the			☐ Yes	□No				
	preferred GLP1-RAs (Trulicity)?	Proceed to question 11	STOP					
				Coverage not approved				
	Will the resucc	tod modication be used with	□ Yes	D No.				
 Will the requested medication be used with another GLP1RA (for example, Bydureon, Trulicity, Byetta, Adlyxin, Victoza, Soliqua, Xultophy)? 	another GLP1RA (for example, Bydureon, Trulicity, Byetta, Adlyxin, Victoza, Soliqua,		STOP	□ No Proceed to question 12				
			Coverage not approved	Froceed to question 12				
	Soverage not approved							

TRICARE Prior Authorization Request Form for liraglutide 3 mg injection (Saxenda), semaglutide 2.4mg injection (Wegovy) tirzepatide injection (Zepbound)

12. Does the patient have a history of or family history of medullary thyroid cancer, or multiple endocrine neoplasia syndrome type 2?	☐ Yes STOP Coverage not approved	□ No Proceed to question 13			
13. Has the patient engaged in a trial of behavioral modification and dietary restriction for at least 6 months and has failed to achieve the desired weight loss, and will remain engaged throughout course of therapy?	☐ Yes Proceed to question 14	□ No STOP Coverage not approved			
14. Is the patient pregnant?	☐ Yes STOP Coverage not approved	□ No Sign and date below			
15. Is the patient currently engaged in behavioral modification and on a reduced calorie diet?	☐ Yes Proceed to question 16	□ No STOP Coverage not approved			
16. How old is the patient?	□ Less than 12 years of age - STOP Coverage not approved □ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question 18 □ Greater than or equal to 18 years of age - Proceed to question 17				
17. Has the patient lost GREATER THAN or EQUAL to 4 percent of baseline body weight since starting medication despite 16 weeks of therapy?	☐ Yes Proceed to question 19	□ No STOP Coverage not approved			
18. Has the patient experienced a reduction of AT LEAST 5 percent of baseline BMI?	☐ Yes Proceed to question 19	□ No STOP Coverage not approved			
19. Is the patient pregnant?	☐ Yes STOP Coverage not approved	□ No Sign and date below			
I certify the above is true to the best of my knowledge. Please sign and date:					
Prescriber Signature	Date	[10 May 2024]			

Step 3